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C-reactive protein (CRP) is routinely assessed as a marker of systemic inflammation in rheumatoid arthritis
(RA). However, it is also an immune regulator that plays an important role in inflammatory pathways associ-
ated with RA and promotes atherogenic effects. Comorbidities linked to systemic inflammation are common
in RA, and CRP has been associated with the risk for cardiovascular disease, diabetes, metabolic syndrome,
pulmonary diseases, and depression. The relationship between systemic inflammation, CRP, and comorbid-
ities in RA is complex, and it is challenging to determine how changing CRP levels may affect the risk or pro-
gression of these comorbidities. We review the biological role of CRP in RA and its implications for disease
activity and treatment response. We also discuss the impact of treatment on CRP levels and whether reduc-
ing systemic inflammation and inhibiting CRP-mediated inflammatory pathways may have an impact on
conditions commonly comorbid with RA.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)c. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Introduction
Rheumatoid arthritis (RA) is a chronic immune-mediated sys-
temic inflammatory disease characterized by chronic synovial inflam-
mation and hyperplasia, which drive joint erosion and damage, and a
range of systemic manifestations, which contribute to overall disease
burden [1]. This results in functional decline, disability, and reduced
quality of life for patients with RA, particularly due to symptoms
such as pain, fatigue, and morning stiffness [15]. Comorbidities are
common in RA and require a holistic management approach, as mul-
tiple comorbidities are associated with poorer clinical outcomes
[68]. Patients with RA have an almost 2-fold higher cardiovascular
(CV) risk than the general population, [9,10] and more than 50% of
premature deaths among RA patients are due to CV disease (CVD)
[11].
Proinflammatory pathways result in localized joint and systemic
inflammation, [1] with cytokines, such as interleukin-6 (IL-6), tumour
necrosis factor-a (TNF-a), IL-1b, as well as downstream signalling
pathways, eg, the Janus kinase (JAK)/signal transducers and activators
of transcription pathway, playing important roles [1,12,13]. One func-
tion of IL-6 is to drive production of the acute-phase reactant C-reac-
tive protein (CRP) following an inflammatory event [1416]. While
CRP is a key marker of systemic inflammation in RA, its overarchingrole in RA and its association with comorbidities has not been com-
prehensively investigated. In this narrative review, we discuss the
role of CRP in RA, focusing on the relationship between CRP and
comorbidities, and the effect of RA treatment on CRP levels and out-
comes. Articles were identified in PubMed using search terms CRP
and RA together with: comorbidity, anaemia, asthma, cancer, chronic
obstructive pulmonary disease (COPD), CVD, diabetes, interstitial
lung disease (ILD), disease-modifying anti-rheumatic drug (DMARD),
methotrexate, TNF inhibitor (TNFi), IL-6, JAK inhibitor, and steroids.
Results were limited to articles in English published in the last
10 years and supplemented by inclusion of relevant citations found
within identified articles.Roles of CRP in RA
In general, CRP plays an important role in host defence mecha-
nisms against infectious agents and in the inflammatory response.
[17,18] CRP binding to immunoglobulin Fc gamma receptors (FcgR)
promotes the production of proinflammatory cytokines leading to an
amplification loop of inflammation [2729]. It is produced predomi-
nantly by hepatocytes in response to stimulation by IL-6, [14,15] but
CRP has also been reported to be expressed by smooth muscle cells,
macrophages, endothelial cells, lymphocytes, and adipocytes (Fig. 1)
[18]. A significant correlation has been seen between serum CRP lev-
els and tissue inflammation scores from knee synovium biopsy sam-
ples in patients with RA (n = 197; p < 0.0001) [46]. Analyses of serum
Fig. 1. The biological role of C-reactive protein (CRP).
C1q, complement component 1q; CRP, C-reactive protein; eNOS, endothelial nitric oxide synthase; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; LDL-C, low-den-
sity lipoprotein cholesterol; mCRP, monomeric CRP; MCP-1, monocyte chemoattractant protein-1; NO, nitric oxide; pCRP, pentameric CRP; RANKL, receptor activator of nuclear fac-
tor-kB ligand; ROS, reactive oxygen species; TNF, tumour necrosis factor; VCAM-1, vascular cellular adhesion molecule-1.
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closely correlate with IL-6 levels [1923].
CRP is an immune regulator  not just a marker of inflammation
or infection [17,18]. There has been controversy over the direct role
of CRP in inflammation and infection, but the identification of CRP
isoforms with different biological properties provided a potential
explanation for conflicting observations [24]. CRP is synthesized in
hepatocytes and secreted into the circulation as pentameric CRP
(pCRP), also known as native CRP. pCRP is thought to act as an
immune regulator [25]. When bound to cell membranes or lipo-
somes, pCRP can irreversibly dissociate via a conformationally
changed intermediate into monomeric CRP (mCRP), which is a
proinflammatory isoform able to activate platelets, leucocytes,
and endothelial cells as well as bind complement component 1q
to activate complement [18,25,26]. mCRP has limited solubility
compared with pCRP and is considered to be tissue bound,
although transmission via microparticles and ligand complexes
has been postulated [25]. Depending on its structural form, CRP
interacts with a variety of leucocytes and endothelial cells, stimu-
lating proinflammatory cytokine release, including IL-6, IL-1b,
and TNF-a, upregulating adhesion molecules, increasing mono-
cyte chemoattractant protein-1 release to recruit monocytes,
inhibiting nitric oxide production, and activating platelets,
thereby inducing proinflammatory and atherogenic effects (Fig. 1)
[18,24,2630]. Reference to CRP hereafter signifies circulating
CRP without distinction between isoform unless specified.
Circulating CRP levels
In healthy adults, plasma CRP concentration is usually <10 mg/L,
although there is considerable inter-individual variability [17,31,32].
CRP levels >10 mg/L are generally considered elevated, although the
normal reference range can differ between assays [33]. Obesity is
associated with elevated CRP levels. [34] Serum CRP levels can be
tested using standard or high-sensitivity (hsCRP) assays; hsCRP isused for evaluation of conditions potentially associated with inflam-
mation in otherwise healthy individuals [33].
CRP levels are often persistently elevated in patients with RA, with
levels of >20 mg/L frequently reported at baseline in randomized
clinical trials (RCTs) of drugs to treat RA [35]. However, retrospective
and observational real-world studies show that many patients have
normal CRP levels despite exhibiting RA disease activity, [36,37] sug-
gesting that CRP levels reflect only one of the signs of disease activity
and should be assessed in the context of other measures. Addition-
ally, multiple factors influence baseline serum CRP levels in patients
with RA. Single nucleotide polymorphisms in CRP and their haplo-
types have been associated with higher or lower CRP levels, [3840]
although no association was found in a prospective observational
study of a patient population with much higher average baseline CRP
levels (34 mg/L) [41]. Body fat, female hormone levels, dietary qual-
ity, and stress have also been shown to influence CRP levels in
patients with RA [4245]. As pharmacological treatments for RA
reduce systemic inflammation, CRP levels generally decrease with
treatment, to differing degrees depending on the drug class and
mechanism of action.
Biological effects of CRP in RA
There is growing preclinical evidence that CRP may play a direct
role in bone destruction in RA. Bone destruction is initiated via induc-
tion of receptor activator of nuclear factor-kB ligand (RANKL) expres-
sion, which stimulates osteoclastogenesis, resulting in bone-
resorption. CRP induces RANKL expression in peripheral blood mono-
cytes and stimulates osteoclast differentiation in the absence of
RANKL [20]. However, the effects of CRP on osteoclast differentiation
might depend on CRP isoform. mCRP has been shown to inhibit
RANKL-induced osteoclast differentiation in vitro, by neutralizing
RANKL, potentially exerting a protective effect [47,48]. Additionally,
patients with RA who have a monocyte imbalance (M1/M2 ratio >1)
exhibit significantly higher levels of CRP than those with M1/M2 ratio
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genesis [49]. More research is needed to fully elucidate the role of
CRP in bone destruction.
CRP as a marker of RA disease activity
Higher CRP levels are associated with greater RA disease activity
based on the core components of the 28-joint Disease Activity Score
(DAS28) [50,51]. Individual aspects of disease activity, such as swol-
len joint count, and patient-reported measures, including functional
status (Health Assessment Questionnaire score), morning stiffness,
fatigue, and pain, have also been associated with CRP [5256].
Indeed, CRP levels are widely used for monitoring systemic inflam-
mation and disease activity in RA. CRP level is a component of several
composite disease activity measures: DAS28-CRP, SDAI, and Ameri-
can College of Rheumatology (ACR) and European League Against
Rheumatism (EULAR) definitions of remission. [5759] Yet, the use-
fulness of CRP testing as a routine measure of RA disease activity is
not universal due to the substantial proportion of treated patients
who experience flares in their RA but still have normal CRP levels. In
fact, as RA clinical trials often specify elevated CRP (for example
6 mg/L) [60] as an eligibility criterion, patients with active RA but
without elevated inflammatory markers are commonly excluded.
Along with disease activity, CRP is known to be associated with
radiological damage in RA. Numerous studies in patients with early
RA have shown that elevated CRP levels both at baseline and using
time-integrated measures correlate with rapid radiological progres-
sion and joint damage within 1 year. [6166] Elevated baseline CRP
levels are also a more general predictive factor for radiographic pro-
gression and joint destruction in patients with early, moderate and
severe RA [64,67,68]. However, a CRP threshold level that could be
used as a marker for radiographic progression has not been estab-
lished.
As noted above, CRP is a standard component of many RA com-
posite disease activity measures (DAS28-CRP, SDAI, ACR/EULAR
remission) [5759]. ACR and EULAR recommend DAS28 using either
CRP or erythrocyte sedimentation rate (ESR) without differentiating
between them in terms of disease activity thresholds [57]. However,
there is evidence that DAS28-CRP scores are consistently lower than
DAS28-ESR values [187189]. Given disease activity thresholds (high
>5.1, low disease activity [LDA] <3.2, and remission<2.6) were origi-
nally validated using DAS28-ESR, using the same thresholds forFig. 2. The interplay of C-reactive protein (CRP) and common comorbidities in RA.
CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CRP, C-reactive
ILD, interstitial lung disease; MACE, major adverse cardiovascular event; MI, myocardialDAS28-CRP may underestimate residual disease activity [187,189].
Consequently, new disease activity thresholds for DAS28-CRP of
>4.6, <2.9, and <2.5 have been proposed. [187,189] Additionally,
there may be challenges in assessing remission with DAS28-CRP
when patients are treated with IL-6 inhibitors and other drugs that
directly affect levels of CRP, as a reduction in CRP may not reflect a
decrease in disease activity. Thus, a more stringent threshold for
DAS28-CRP remission of <1.9 has been proposed [190]. Moreover,
many patients with active RA may not have an elevated CRP and this
is a common reason for screen failures in RA treatment trials
[36,191].
Association of CRP with comorbidities in RA
There is a high prevalence of comorbidities in patients with RA,
the most common of which include CVD, metabolic syndrome, diabe-
tes, pulmonary diseases, and depression [6]. While the biological
relationships between CRP levels and comorbidities in RA have not
been fully established, elevated CRP levels have been shown to be
associated with an increased risk for several common comorbidities
(Fig. 2). Understanding these associations is important from a clinical
perspective to help in the identification of patients at risk for comor-
bidities, especially those that may be associated with an increased
risk for mortality.
Cardiovascular comorbidities
Data from large observational cohorts have shown that RA is asso-
ciated with an up to 2-fold increased CV risk compared with the gen-
eral population, [9,10,69,70] including reported increased risks of
myocardial infarction (MI; 3396%), [7072] heart failure (6187%),
[70,72] stroke (2429%), [71] and major adverse CV events (MACE;
3058%), [71,73] along with a 50% higher incidence of CV-related
mortality, [71,74] independent of traditional CV risk factors. In a
meta-analysis, the relative risk for patients with RA to develop CVD
was age dependent, with higher CV risk seen in patients aged <50
than 5065 or >65 years (risk ratio (RR) 2.59, 1.86, and 1.27 versus
the general population). [75] Moreover, there is evidence from epide-
miological studies of a strong association between CRP and IL-6 levels
and CV risk. [7679] In the general population, CRP is considered an
independent predictor of CV risk, [80,81] with a 58% increased risk
for coronary heart disease with CRP levels >3.0 versus <1.0 mg/Lprotein; HBV, hepatitis B; HCV, hepatitis C;
infarction; RA, rheumatoid arthritis.
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cohort studies have reported associations between elevated CRP lev-
els in RA and a more atherogenic lipid profile and hyperlipidaemia,
[83,84] an increased risk for MI (hazard ratio [HR] 2.12, 95% CI
1.024.38 for CRP >10 versus <1 mg/L), [85] heart failure (HR 1.25,
95% CI 1.061.48 per 100 mg/L increase in CRP), [86] stroke (HR 2.02,
95% CI 1.323.08 for CRP >21.7 mg/L versus <2.6 mg/L), [87] and CV-
related death (14% increase for each mg/L and HR of 3.3 [95% CI
1.47.6] for CRP 5 mg/L) [88,89]. Higher CRP levels also increase risk
for atherosclerosis and increase subclinical atherosclerosis as measured
by carotid intimamedia thickness in patients with RA [9094].
Systemic inflammation is a key driver of atherosclerosis. Specifi-
cally, CRP has been shown to have a direct biological role in the
development and progression of atherosclerosis and thrombosis [82].
CRP increases during the progression of atherosclerosis and can acti-
vate the complement system, inducing apoptosis, and contributes to
endothelial dysfunction by inhibiting nitric oxide and upregulating
endothelial cell adhesion molecules. It also promotes monocyte
recruitment into atherosclerotic plaques and increases the inflamma-
tory response by inducing leucocyte adhesion and migration and
generation of reactive oxygen species (Fig. 1). CRP also contributes to
plaque instability by inducing metalloproteinase expression and pro-
motes thrombus growth via induction of platelet activation.
A reduction in disease activity in RA has been shown to be associ-
ated with a reduction in CV risk in numerous studies. Indeed, data
from the longitudinal CORRONA registry demonstrated that a 10-
point reduction in time-averaged CDAI was associated with a 21%
decrease in CV risk [95]. In a meta-analysis of clinical studies, metho-
trexate and TNFis each appeared to reduce the CV risk by approxi-
mately 30% (RR 0.72, 95% CI 0.570.91, p = 0.007 and RR 0.70, 95% CI
0.540.90, p = 0.005, respectively) [96]. Abatacept showed a modest
reduction in risk for a composite CV endpoint compared with TNFis
in a large population-based RA cohort (HR 0.86, 95% CI 0.731.01)
[97]. Despite the known effect of IL-6 inhibitors for increasing lipid
levels, [98] in the randomized, open-label ENTRACTE trial, the esti-
mated risk for MACE was similar between tocilizumab (an IL-6R
inhibitor) and etanercept (HR 1.05, 95% CI 0.771.43) [99]. Likewise,
an integrated safety analysis of clinical trials of the IL-6R inhibitor,
sarilumab, reported exposure-adjusted incidence rates of MACE of
0.20.5/100 patient-years, comparable to the incidence in the gen-
eral RA population (1.2/100 patient-years) [100]. Pooled safety analy-
ses for JAK inhibitors report similar incidence rates of MACE for
tofacitinib of 0.4/100 patient-years and baricitinib (4 mg) of 0.8/
100 patient-years. [101,102] Further research is needed to determine
whether the biological link between elevated CRP in RA and in CVD
and the reduction in CRP levels during treatment for RA contributes
to the reduction in CV risk reported in these studies.
Metabolic syndrome
The prevalence of metabolic syndrome appears to be greater in
patients with RA than the general population, with rates of 3040%
reported compared with about 20% in controls [103107]. Higher
CRP levels have been associated with increased prevalence of meta-
bolic syndrome in RA, [107,108] greater abdominal adiposity, [109]
decreased insulin sensitivity, [110114] and increased lipid levels
[83]. However, two North American cross-sectional cohort studies
did not find a significant association between CRP and metabolic syn-
drome in patients with RA (odds ratio [OR] about 1 in both studies).
[103,106] CRP levels have been associated with lipid abnormalities,
[77,115] negatively correlating with high-density lipoprotein choles-
terol (HDL-C) [116]. However, a direct biological link between CRP
levels and metabolic syndrome in RA has yet to be established.
Conventional synthetic DMARDs (csDMARDs), targeted synthetic
DMARDs (tsDMARDs), and bDMARDs all increase lipid levels,
[117121] but TNFis improve insulin resistance and sensitivity,[122124] and tocilizumab does not appear to significantly affect
body mass index, waist circumference, or atherogenic index
[118,125]. so the overall impact of RA treatments on metabolic syn-
drome is, as yet, not firmly established.Diabetes
Patients with RA are up to twice as likely to be diagnosed with
diabetes mellitus (DM) than are the general population, [126128]
and the prevalence of DM in RA is about 1320%. [6,126,129] Higher
CRP levels have been seen in RA patients with type 2 diabetes
(T2DM) compared with those without [126]. High CRP levels in RA
have also been correlated with impaired glucose tolerance and
metabolism and to insulin resistance, [130] and are significantly asso-
ciated with small increased likelihood of impaired fasting glucose (OR
1.02, 95% CI 1.0011.034, p = 0.02) [128]. Significant positive associa-
tions between the homeostatic model assessment of insulin resis-
tance and CRP and IL-6 levels have also been seen in patients with
RA. [111,113,114] However, as for metabolic syndrome in RA, no
direct biological link between CRP levels and diabetes in patients
with RA has yet been established.
There is evidence that treatment with DMARDs may reduce the
risk for T2DM, [131133] and reduce glycosylated haemoglobin lev-
els (HbA1c) [134] in patients with RA. In the CORRONA registry, treat-
ment with TNFis significantly reduced the risk for T2DM (OR 0.35,
95% CI 0.130.91, p = 0.03), while other bDMARDs (OR 0.44, 95% CI
0.082.57, p = 0.36), methotrexate (OR 0.67, 95% CI 0.441.02,
p = 0.34), and hydroxychloroquine (OR 0.45, 95% CI 0.131.53,
p = 0.21) numerically reduced the risk for T2DM versus patients
treated with other csDMARDs [133]. In contrast, the risk for T2DM
escalates with increasing doses of glucocorticoids (HR 2.33, 95% CI
1.683.22, p = 0.02 for patients using 7.5 mg glucocorticoid versus
no glucocorticoid) [133]. In a retrospective analysis in Japan, HbA1c
levels significantly decreased after 3 months of treatment with either
TNFis or tocilizumab (p < 0.001 for both treatments) in patients with
RA, including in the subgroup of patients with DM. In this analysis,
tocilizumab was associated with greater reductions in HbA1c levels
than were TNFis (OR 5.59, 95% CI 2.5612.2, p < 0.001) [134]. In a
post-hoc analysis of sarilumab phase III trials, patients with RA and
diabetes had greater improvements in HbA1c with sarilumab 200 mg
every 2 weeks (q2w) than with adalimumab 40 mg q2w
(0.43 versus 0.02 at 24 weeks) or placebo (0.60, 0.33, and 0.18
at 24 weeks for sarilumab 200 mg, 150 mg, and placebo q2w, respec-
tively) [135]. Given the prevalence of DM in RA, the decrease in risk
for T2DM and improvements in HbA1c levels with different DMARD
treatments should be considered when personalizing RA treatment.Pulmonary disease
RA is associated with a 70100% increased risk for COPD com-
pared with controls, [136139] and the prevalence of COPD among
RA patients is about 48%. [6,137,138] COPD has been shown to
increase the risk for mortality almost 3-fold in patients with RA.
[140,141] High CRP levels have been associated with increased risk
for COPD, [142] and higher CRP levels are seen in patients with stable
COPD than controls [143,144]. As COPD exacerbations are often
caused by infections, the finding that CRP levels are significantly
higher in patients with acutely exacerbated versus stable COPD
(p < 0.05) is not surprising [144]. In the USA NHANES survey, ele-
vated CRP (>10 mg/L) was associated with increased risk for mortal-
ity (HR 4.45, 95% CI 1.9110.37) in patients with COPD, [145] and a
separate analysis showed that CRP 3 mg/L was associated with
increased mortality (HR 1.61, 95% CI 1.122.30) [146]. CRP levels
3 mg/L in stable COPD are associated with poor predicted forced
vital capacity and patient-reported health status [147,148].
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to more frequent respiratory adverse events seen among patients
with COPD in the ASSURE trial, the risk for COPD exacerbations with
abatacept has recently been described [149]. In retrospective popula-
tion-based cohort studies of patients with RA and COPD, abatacept
was not associated with significantly increased risk for COPD exacer-
bation or respiratory adverse events compared with csDMARDs,
tsDMARDs, TNFis, or other bDMARDs [150,151]. Data from RCTs for
patients with RA and comorbid COPD would be valuable to further
investigate the effects of DMARD treatment to determine whether
reducing the generally higher CRP levels seen in patients with RA
may impact positively their COPD.
The lifetime risk for patients with RA developing ILD has been
reported at 615%, compared with 1% for the general population
[152,153]. ILD may occur before the development of articular mani-
festations in RA [152,154,155]. A population-based study in Denmark
found that 14% of ILD cases in patients with RA were diagnosed
15 years before RA diagnosis, and 34% within 1 year prior to and 1
year after RA diagnosis [155]. Pulmonary abnormalities compatible
with ILD were present in 21/36 patients (58%) with recent onset RA
(duration of joint symptoms <2 years) who were referred to a uni-
versity rheumatology department [156]. The main risk factors for
developing RA-ILD are smoking, older age, male sex, rheumatoid fac-
tor, and anti-cyclic citrullinated peptide antibody levels [154,157]. Of
the RA-ILD subtypes, usual interstitial pneumonia (UIP) is generally
the most common, followed by non-specific interstitial pneumonia
(NSIP) [157,158]. RA-ILD is associated with poor prognosis, with haz-
ard rate ratios for death 210 times higher in RA-ILD than in RA
without ILD [155]. Patients with a UIP histological pattern have the
worst prognosis, with mortality rates similar to those observed
among patients with idiopathic pulmonary fibrosis [159162].
It is uncertain if high CRP is related to progression of ILD in RA.
Although higher CRP levels in patients with RA-ILD versus RA with-
out ILD have been observed in several retrospective studies in Asia,
[163165] this pattern was not seen in an Italian retrospective study
[166]. Additionally, the association of high CRP levels with risk for
ILD was not significant in a multivariate analysis in Chinese patients,
suggesting that CRP level may not be an independent risk factor for
ILD [163].
Depression
Depression is highly prevalent in patients with RA, with a
reported prevalence of 1540%, and it is more common in patients
with RA than in the general population [6,167]. Elevated CRP, TNF-a,
and IL-6 levels have been noted in some studies in RA patients with
depression [168,169]. Elevated CRP has been associated with higher
depression scores in patients with RA [170172]. However, the asso-
ciation between systemic inflammation and depressive symptoms is
complicated by factors such as pain and disease activity, which may
attenuate the link between CRP and depression [170172].
The relationship between depression and treatment response in
RA appears to be bidirectional. In the CARDERA RCT in patients with
early RA who received methotrexate or methotrexate plus predniso-
lone and/or cyclosporine, patients reporting persistent depression/
anxiety were significantly less likely (6290%; p < 0.05) to achieve
clinical remission (DAS28 <2.6) over 2 years [173]. In a large UK
observational study, depressive symptoms at baseline did not predict
non-response to methotrexate after 6 months of treatment [174].
Additionally, compared with RA patients without depressive symp-
toms, patients with depressive symptoms at bDMARD initiation were
2040% less likely to achieve a EULAR good treatment response after
1 year [175]. Conversely, in a USA retrospective observational study,
patients with RA but no depressive symptoms at baseline who
responded to TNFi treatment were 20% less likely to develop depres-
sion than were non-responders (7.1% versus 9.4%; p < 0.005;adjusted OR 0.80, 95% CI 0.640.98) [176]. Etanercept has also shown
small but significant effects (728%) in reducing depression scores
compared with methotrexate in patients with RA [177]. Analyses of
patient-reported outcomes in phase III trials in RA showed improved
Mental Health and Role Emotional domain scores of Short Form 36
with sarilumab, tocilizumab, and tofacitinib [178180]. Further, in
an interim analysis of the ARATA study of tocilizumab treatment in
routine practice, tocilizumab improved depressive symptoms over
2 years, [181] and in the ACT-AXIS prospective observational study,
tocilizumab significantly decreased depression score (p < 0.005).
[182] Given the complex interplay of depression with RA disease
activity, inflammation, and RA symptoms, poorer RA treatment out-
come may be influenced, at least in part, by presence of depressive
symptoms [183].
Clinical implications of CRP in the management of patients with
RA
Circulating CRP level is routinely tested, as it is an inexpensive and
readily available biomarker to assess systemic inflammation and clin-
ical outcomes in RA. CRP levels can be assessed via standard or hsCRP
assays, with values <10 mg/L and <1 mg/L, respectively, generally
considered normal, although thresholds may differ between assays
[33,184]. In RA, given the generally elevated levels of CRP due to sys-
temic inflammation, the hsCRP assay is typically considered unneces-
sary. There are limitations of conventional CRP testing: for the
substantial proportion of patients who have normal CRP levels while
exhibiting RA disease activity or flare, [36,37] a low CRP level may
provide false reassurance of reduced inflammation. Additionally,
while CRP is a marker of systemic inflammation, it is not useful as an
independent factor for predicting the risk for developing RA,
[185,186] and it does not confirm a diagnosis of RA. In the context of
comorbidities in RA, a specific CRP level/threshold is not a predictor
for any particular comorbidity.
Screening for CV risk factors in patients with RA
Given the increased morbidity and mortality associated with CVD
in RA compared with the age- and gender-matched population, CV
risk should be assessed for all patients [192]. General CV risk calcula-
tors, such as SCORE and the Framingham risk score, may underesti-
mate the CV risk in RA, and RA-specific calculators like EULAR
multiplier and expanded CV risk prediction score (ERS-RA) do not
appear to perform better than the general risk calculators [193,194].
The Reynolds risk score is the only measure that includes CRP, and it
may be sensitive to the fluctuating inflammation seen in patients
with RA [195]. The addition of CRP to the Framingham risk score and
QRISK algorithms was not associated with significant improvement
in reclassification of CV risk [196]. There is controversy about which
risk calculator to use as the rates of CV events in people with RA are
decreasing, but so are those of the matched population, so a gap still
exists with more CV events in RA [197,198].
Effects of treatment for RA on CRP levels
Treatment of RA with DMARDs aims to reduce systemic inflam-
mation and improve disease activity. As a measure of systemic
inflammation it would be expected that CRP levels will fall in
response to treatment and indeed this is observed during treatment
with the different DMARD classes as shown in Supplementary Table
1. Corticosteroids and csDMARDs lead to small decreases in CRP lev-
els [60,199205]. TNFis decrease CRP levels, generally slightly more
than csDMARDs in equivalent patient populations [41,206209]. JAK
inhibitors that target downstream signalling pathways of IL-6 and
other cytokines decrease CRP levels by about 10 mg/L, with the
reduction tending to be dose dependent [205,209211]. Overall, the
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response to treatment with IL-6R inhibitors, generally resulting in
normalization of CRP levels [60,200,201,207,212,213]. Given the pre-
dominant role of IL-6 in stimulating CRP production, these results are
not surprising.
Consistent with the decreases in CRP levels resulting from IL-6
inhibition, improvements in clinical outcome measures that include
CRP have been reported. Indeed, clinical trials have demonstrated
that treatment with sarilumab (MOBILITY, MONARCH, and TARGET)
results in improvements in DAS28-CRP scores (up to 2.8-point
decreases) and higher rates of DAS28-CRP LDA and remission (using
standard thresholds of 3.2 [3349%] and <2.6 [2534%]) and of
ACR20/50/70 response [6172%/4046%/1625%] compared with
placebo or, in MONARCH, with adalimumab [60,200,206]. Similar
levels of efficacy have been seen with tocilizumab in the BREVACTA
and SUMMACTA studies [204,214]. Higher rates of SDAI remission
with tocilizumab than with TNFi treatment have also been seen in a
real-world observational study (SDAI 3.3 32% versus 22%, p < 0.05
at Week 52) [207]. The JAK inhibitor upadacitinib demonstrated
superiority to adalimumab for DAS28-CRP LDA and remission in a
phase III trial of patients with RA and an inadequate response to
methotrexate [215]. Importantly, RA drugs that influence CRP levels
have also been shown to improve RA disease activity using scores
that do not include a CRP component, indicating their effects on dis-
ease activity in RA extend beyond those driven by systemic inflam-
mation. For example, in the most recent sarilumab phase III trial
(MONARCH), the primary efficacy endpoint was change in DAS28-
ESR at 24 weeks, and sarilumab produced significantly greater
improvement than adalimumab (3.28 versus 2.20, respectively;
p < 0.0001) [206].
Subgroup analyses of IL-6R inhibitor RCTs are suggestive of how
clinical outcomes may be associated with CRP. Evaluation of baseline
CRP subgroups in MOBILITY and MONARCH showed that the treat-
ment effect of sarilumab was greater in the group with baseline CRP
>15 mg/L both for radiographic progression (mean modified total
Sharp score change at Week 52, sarilumab 0.901.00 versus placebo
4.25) [216] and for greater improvement versus adalimumab even
when using the DAS28-ESR score [217]. In MOBILITY, patients receiv-
ing sarilumab who achieved DAS28-CRP <3.2 versus those who did
not exhibited a slightly greater percentage decrease from baseline in
CRP after 24 weeks (97% versus 90%, nominal p< 0.01) [218]. Sim-
ilar trends were seen in TARGET for ACR50 responders versus non-
responders [201]. However, despite the link between IL-6 inhibition
and CRP levels, CRP does not appear to be a consistent predictive bio-
marker for response to tocilizumab treatment. An analysis of BRE-
VACTA and SUMMACTA demonstrated that baseline CRP levels were
not predictive of clinical outcomes after tocilizumab treatment [213].
In contrast, the RADIATE study demonstrated that tocilizumab treat-
ment led to a significant decrease in a matrix metalloproteinases-
degraded fragment of CRP, reducing tissue inflammation, with the
decrease correlating with improvements in pain, functional status,
DAS28, and the likelihood of ACR20/50 response [219]. Overall, fur-
ther investigation of the relationship of baseline and change in CRP
levels with clinical outcomes after IL-6 inhibition is needed to under-
stand how they are linked.
There is extremely limited evidence on whether changes in CRP
levels resulting from DMARD treatment may also affect the risk for
developing or exacerbating common comorbidities. In a single-centre
longitudinal cohort study of 90 patients with RA who were receiving
DMARDs and experienced reductions of CRP >10 mg/L, increases in
low-density lipoprotein cholesterol levels and improvements in HDL-
C efflux capacity suggested that reducing systemic inflammation
improved the lipid profile and potentially reduced CV risk [115].
However, the relationship between reducing CRP levels and a poten-
tial reduction in CV risk remains to be elucidated. More research is
needed to investigate specific associations between reductions inCRP levels resulting from DMARD treatment and the impact on
comorbidities.
In conclusion, CRP is a valuable marker and regulator of systemic
inflammation in RA that also appears to play a direct role in bone
destruction and radiographic progression. CRP has also been impli-
cated in the aetiology of common comorbidities associated with RA.
Reducing CRP levels with RA treatment may contribute to reductions
in disease activity, although beneficial effects of RA treatment seem
to occur irrespective of CRP values.
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